[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651982":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":22,"locations":10,"responsibleParty":31,"collaborators":10,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":10,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":10},{"fullName":5,"class":6},"Sohag University","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Malignant pleural effusion",null,[12],"Diagnostic Test: Cancer Ratio and Cancer Ratio Plus",{"label":14,"type":10,"description":10,"interventionNames":15},"Tuberculous pleural effusion",[12],[17],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"DIAGNOSTIC_TEST","Cancer Ratio and Cancer Ratio Plus","Cancer Ratio and Cancer Ratio Plus will be calculated using serum LDH, pleural fluid ADA, and pleural fluid lymphocyte percentage to assess their diagnostic value in differentiating malignant pleural effusion from tuberculous pleural effusion.\n\n1. Cancer Ratio CR =Serum LDH \u002Fpleural fluid ADA .\n2. Cancer Ratio Plus = Serum LDH\u002F(pleural fluid ADA × pleural fluid Lymphocyte fraction )",[9,14],[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Dina MA Mohamed Ahmed, M.B.B.Ch.","CONTACT","+201112561650","Dina.Mohamed@med.sohag.edu.eg",{"name":29,"role":25,"phone":30,"phoneExt":10,"email":10},"Enas K Ahmed, Lecturer","+201022937527",{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Dina Mohamed Ahmed","Resident doctor at chest diseases department","100651982","cancer-ratio-and-cancer-ratio-plus-in-malignant-and-tuberculous-pleural-effusions-100651982",false,"NCT07766876","Cancer Ratio and Cancer Ratio Plus in Malignant and Tuberculous Pleural Effusions","Role of Cancer Ratio and Cancer Ratio Plus in the Differentiation Between Malignant and Tuberculous Pleural Effusions .","CRPLUS-MPE-TPE","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* Patients with Malignant or tuberculous pleural effusion\n* Availability of complete pleural fluid analysis including lymphocyte percentage ,pleural fluid ADA, and Serum LDH level\n\nExclusion Criteria:\n\n* Patients with mixed etiology effusions (e.g., malignancy with infection)\n* Prior pleural interventions affecting fluid analysis\n* Incomplete clinical or laboratory data","ALL","18 Years",{"count":46,"type":47},120,"ESTIMATED","OBSERVATIONAL","This prospective observational analytical study aims to assess the diagnostic value of Cancer Ratio and Cancer Ratio Plus in differentiating malignant pleural effusion from tuberculous pleural effusion. Adult patients with confirmed malignant or tuberculous pleural effusion will be recruited from the Chest Diseases Department, Sohag University Hospitals. Clinical, laboratory, and radiological data will be collected, and the diagnostic performance of both markers will be evaluated.",[51,52],"Malignant Pleural Effusion","Tuberculous Pleural Effusion",[54,55,56,57,58],"Cancer ratio","Cancer ratio plus","Serum LDH","Pleural fluid ADA","Pleural fluid analysis","NOT_YET_RECRUITING","2026-08-11",{"date":62,"type":63},"2026-08-17","ACTUAL",{"date":65,"type":47},"2026-09-01",{"date":67,"type":47},"2027-08-31",{"name":5,"class":6}]